Domain Therapeutics is a leading biopharmaceutical company in the field of G Protein- Coupled Receptors (GPCRs), one of the most important classes of drug targets. We are dedicated to consolidating this position by developing a high-value pipeline of innovative drug candidates. To achieve this, we will continue to focus on identification of new class of treatments by leveraging our expertise, innovative approach and proprietary technologies as well as our strong company culture. In addition to expand our preclinical portfolio, we will also move forward the pipeline into the clinics.
With our teams present in Europe and North America, we create a pipeline of high-value programs in immuno-oncology, neurologic disorders and rare diseases which we develop as proprietary programs up to early clinical phases, in collaboration with pharma partners or through asset-centric companies. These vehicules benefit from dedicated teams and targeted investments for a focused development. Exit is through a trade sale at an appropriate inflection point.